Pioglitazone for the treatment of Alzheimer’s disease

References

• Reitz C, Brayne C, Mayeux R. Epidemiology of Alzhiemer disease. Nat Rev Neurol. 2011;7:137–152.
   PubMed Web of Science ®Google Scholar
• Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25:115–126.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AL, Kuller LH, Lopez OL, et al. Survival following dementia onset: Alzheimer’s disease and vascular dementia. J Neurol Sci. 2005;229:43–49.
   PubMed Web of Science ®Google Scholar
• Galimberti D, Scarpini E. Progress in Alzheimer’s disease. J Neurol. 2012;259:201–211.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL, Pontecorvo MJ, et al. The cholinergic hypothesis: a historical overview, current perspective, and future directions. Ann NY Acad Sci. 1985;444:332–358.
   PubMed Web of Science ®Google Scholar
• Knowles J. Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evid. 2006;1:195–219.
   PubMedGoogle Scholar
• Amanatkar HR, Grossberg GT. Transdermal rivastigmine in the treatment of Alzheimer’s disease: current and future directions. Expert Rev Neurother. 2014;14:1119–1125.
   PubMed Web of Science ®Google Scholar
• Jiang D, Yang X, Li M, et al. Efficacy and safety of galantamine treatment for patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Neural Transm. 2015;122:1157–1166.
   PubMed Web of Science ®Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;CD001747.
   PubMed Web of Science ®Google Scholar
• Scarpini E, Bruno G, Zappalà G, et al. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer’s disease: a randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis. 2011;26:211–220.
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.
   PubMed Web of Science ®Google Scholar
• Kurz A, Grimmer T. Efficacy of memantine hydrochloride once-daily in Alzheimer’s disease. Expert Opin Pharmacother. 2014;15:1955–1960.
   PubMed Web of Science ®Google Scholar
• Giacobini E, Gold G. Alzheimer disease therapy–moving from amyloid-β to tau. Nat Rev Neurol. 2013;9:677–686.
   PubMed Web of Science ®Google Scholar
• Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care. 2004;27(7):1660–1667.
   PubMed Web of Science ®Google Scholar
• Ko GJ, Kang YS, Han SY, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant. 2008;23(9):2750–2760.
   PubMed Web of Science ®Google Scholar
• Sims-Robinson C, Kim B, Rosko A, et al. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010;6(10):551–559.
   PubMed Web of Science ®Google Scholar
• Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr Alzheimer Res. 2011;8:592–606.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.clinicaltrials.gov/ct2/results?term=NCT01931566&Search=Search
   Google Scholar
• Geldmacher DS, Fritsch T, McClendon MJ, et al. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol. 2011;68:45–50.
   PubMedGoogle Scholar
• Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005;128:1442–1453.
   PubMed Web of Science ®Google Scholar
• Yamanaka M, Ishikawa T, Griep A, et al. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci. 2012;32:17321–17331.
   PubMed Web of Science ®Google Scholar
• Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J Neurosci. 2003;23(20):7504–7509.
   PubMed Web of Science ®Google Scholar
• Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci. 2012;32:10117–10128.
   PubMed Web of Science ®Google Scholar
• Toba J, Nikkuni M, Ishizeki M, et al. PPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer’s disease model mice. Biochem Biophys Res Commun. 2016;473(4):1039–1044.
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Laitila J, Neuvonen PJ, et al. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006;99:44–51.
   PubMed Web of Science ®Google Scholar
• Al-Majed A, Bakheit AH, Abdel Aziz HA, et al. Pioglitazone. Profiles Drug Subst Excip Relat Methodol. 2016;41:379–438.
   PubMedGoogle Scholar
• Available from: https://www.clinicaltrials.gov/ct2/results?term=NCT01456117&Search=Search
   Google Scholar
• Available from: https://www.clinicaltrials.gov/ct2/results?term=NCT00982202&Search=Search
   Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34:939–944.
   PubMed Web of Science ®Google Scholar
• Moon JH, Kim HJ, Yang AH, et al. The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol. 2012;15:135–142.
   PubMed Web of Science ®Google Scholar
• Bekris LM, Galloway NM, Montine TJ, et al. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet Part B. 2010;153B:409–417.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.clinicaltrials.gov/ct2/results?term=NCT02284906&Search=Search
   Google Scholar
• Muller T, Foley P. Clinical drug research in chronic central neurodegenerative disorders. Expert Rev Neurother. 2016;16(5):497–504.
   PubMed Web of Science ®Google Scholar
• Roses AD, Lutz MW, Crenshaw DG, et al. TOMM40 and APOE: requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. Alzheimers Dement. 2013;9:132–136.
   PubMed Web of Science ®Google Scholar